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lasma glucose is ﬁltered freely through the glo-
merular barrier. In a 70-kg adult with a glomeru-
lar ﬁltration rate of 120 mL $ min
-1 per 1.73 m
2
and an average, around-the-clock plasma glucose
concentration of 120 mg/dL (6.7 mmol/L), ;200 g of glu-
cose are transferred daily from the bloodstream into the
preurine. If nothing else happened, the whole-body mass
of free glucose (some 20 g in a distribution volume of
250 mL/kg) would be emptied out in less than 3 h. What
prevents this catastrophe is, on the one hand, virtually
complete glucose reabsorption at the level of the kidney
and on the other hand, a precisely matched modulation of
endogenous glucose release (chieﬂy by the liver and pos-
sibly also by the kidney itself).
The kidney is well engineered to perform coupled glu-
cose and sodium reabsorption. In the S1/S2 segment of
the proximal tubule, a member of the sodium glucose
transporter (SGLT) family of transmembrane proteins,
SGLT-2—encoded in the SLC5 gene—is expressed at high
levels and cotransports ﬁltered glucose and sodium into
the tubular cell cytoplasm. Downstream to the S1/S2 seg-
ment along the S3 segment of the proximal tubule, an-
other SGLT isoform—SGLT-1, abundantly expressed in
the enterocyte—also performs coupled sodium-glucose co-
transport. At the basolateral membrane of the tubular cell,
a glucose transporter of a different family, GLUT-2, affects
the transfer of intracellular glucose to the interstitium by
a facilitated transport process (via Na
+-K
+-ATPase).
Recent detailed physiological studies (1) in human
embryonic kidney (HEK293T) cells coexpressing human
SGLT-2 and SGLT-1 have established that, contrary to a
long held belief (2,3), the two isoforms have similar afﬁnity
for glucose (in the 2–5 mmol/L range), high afﬁnity for
sodium but different sodium:glucose stoichiometry (1:1 for
SGLT-2 and 2:1 with SGLT-1), and similar electrogenicity.
The proportion of in vivo renal glucose reabsorption due
to the activity of each of the two transporters is a complex
function on their in-series anatomical arrangement, their
differential sodium coupling ratio, copy number, and pro-
tein turnover rate.
The in vivo kinetics of renal glucose handling are sche-
matically depicted in Fig. 1. As plasma glucose concen-
trations and glucose ﬁltration rates increase, reabsorption
rises linearly to its maximum (TmG) at a splayed plasma
glucose threshold (traditionally, 180 mg/dL), after which
excretion linearly begins to increase. The simulation in Fig. 1
shows the effect of lowering TmG by 30%: the leftward shift
in the excretion curve predicts signiﬁcant glycosuria—up
to 30 g daily—within a glucose concentration interval of
150–130 mg/dL. With a 50% reduction in TmG, glycosuria
would appear at a plasma glucose level of 90 mg/dL and
rise to 80 g per day at a plasma glucose of 150 mg/dL, i.e.,
within the normoglycemic range.
Early clinical studies in patients with type 2 diabetes
showed that the TmG is increased by 20–40% in compari-
son with nondiabetic subjects (4). The same ﬁnding has
been reported in patients with type 1 diabetes (5). More
recent studies in cultured human renal tubular cells har-
vested from the urine of diabetic patients have shown that
the expression of SGLT-2, its protein concentration, and
its a-methyl-glucose transport capacity are all increased
markedly in comparison with nondiabetic subjects (6).
Thus, whether it is an intrinsic defect of diabetes or a re-
sult of chronic hyperglycemia, renal glucose reabsorption
appears to be abnormally high in subjects with diabetes. At
the other end of the spectrum is familial renal glycosuria, a
rare disorder caused by private missense or nonsense mu-
tations and deletions in the SLC5A2 gene. Affected patients
excrete between 1–170 g per day of glucose in the urine
according to whether they are homozygous, heterozygous,
or compound heterozygous (7). The condition is benign, as
these patients do not develop renal disease even in the long
term and are not reported to be prone to, and in fact may be
protected against, diabetes and obesity. Finally, in an ex-
perimental model of diabetes, the 90% pancreatectomized
rat (8), the peripheral and hepatic insulin resistance, and the
b-cell defect that these animals develop have been shown to
be fully reversed by a 4-week treatment with phlorizin, a
nonspeciﬁc inhibitor of SGLT-2 and SGLT-1. The effects of
t h ed r u gw e r ea b o l i s h e du p o ni t sw i t h d r a w a l .
The article by Jurczak et al. (9) in this issue of Diabetes
closes the loop on the SGLT-2 story by carefully describ-
ing the phenotype resulting from the deletion of SGLT-2 in
mice bred onto a db/db strain background. SGLT-2-null
mice develop massive glycosuria with normal serum elec-
trolytes, no histopathologic changes in the tubular neph-
ron, drink and eat more, and expend more energy.
Metabolically, they are protected from hyperglycemia
and high-fat–induced weight gain and show modestly
enhanced insulin sensitivity in the liver. b-Cell function
is improved in vivo but not ex vivo in isolated/perifused
islets; islets and b-cell mass are increased because of
slower b-cell death rates.
Collectively, these ﬁndings prove that reduced SGLT-2
activity—whether genetically or experimentally induced—
is efﬁcacious and relatively safe in lowering hyperglycemia
and its toxicity with the added beneﬁts of a degree of
weight control and some natriuresis. The development of
SGLT-2 inhibition as a therapeutic target in type 2 diabetes
is therefore logical and attractive (10–14).
As the story unfolds, interesting questions emerge.
Firstly, hypoglycemia typically does not occur with SGLT-2
inhibition, a key therapeutic value. Clearly, the liver must
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COMMENTARYreact to the glycosuria by increasing glucose release, but
how does it know that the kidney is leaking glucose? The
ﬁndings by Jurczak et al. (9) in SGLT-2
2/2 mice suggest
that liver glycogen depletion and/or slight decrements in
plasma glucose may signal the liver to open up. Also, the
increased reliance on fatty acids for energy production
may imply further substrate or neural mechanisms. If
preventing hypoglycemia is one good job the liver does,
glucose output usually is not reduced enough to attain
normoglycemia in the diabetic patient treated with SGLT-2
inhibitors (10–14). How does the liver know when to stop?
The second issue is that complete blockade of renal
glucose reabsorption is never achieved with selective
SGLT-2 inhibition. Even SGLT-2-null mice reabsorb one-third
of the ﬁltered glucose (15), and dapaglifozin—a selective
SGLT-2 inhibitor in phase III clinical development—causes
at most ;50% inhibition at the highest doses (16), whereas
the nonselective inhibitor, phlorizin, completely blocks
reabsorption. Perhaps SGLT-1 plays a greater role in the
kidney than previously thought (1). Regulation of SGLT-2
expression by glycemia, binding kinetics of glucose and
inhibitor concentrations in the lumen of the proximal
tubule, and the impact of declining glomerular ﬁltration
are additional levels of complexity that need to be ex-
plored.
Finally, the increased calorie intake that follows SGLT-2
inhibition in transgenic mice (9) and, very likely, in di-
abetic patients (12–14) is intriguing. The resemblance to
the hyperphagia of acute diabetic patients points toward
energy-sensing pathways triggered by glycosuria, relaying
at speciﬁc brain areas, and feeding forward to the liver to
modulate glucose production (17). In this connection, it is
of further interest that functional expression of SGLTs has
recently been mapped to several brain regions, including
the hypothalamus (18).
Clearly, glycosuria has gone a long way from a mere
symptom of decompensated diabetes to a tool to learn
more physiology and, in all likelihood, to help to treat
glucose toxicity in man.
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FIG. 1. Renal glucose handling. Flux rates (ﬁltration, reabsorption,
and excretion) were calculated using a glomerular ﬁltration rate of
120 mL $ min
-1 per 1.73 m
2 and a renal threshold of 180 mg/dL (10 mmol/L).
To visualize the splay, data were ﬁtted with polynomials. The dotted
lines simulate the effect of a 30% reduction in TmG on reabsorption and
excretion.
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